Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229290 | 0.90 | CCR1 (0.58) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1639474 | 0.90 | CCR1 (0.75) | CCR1CYP2C19KCNH2 | |
| SCHEMBL10063611 | 0.89 | CCR1 (0.56) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1638717 | 0.89 | CCR1 (0.74) | CCR1CYP2C19KCNH2 | |
| SCHEMBL12766295 | 0.88 | CCR1 (0.73) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1639649 | 0.88 | CCR1 (0.73) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1637482 | 0.88 | CCR1 (0.73) | CCR1CYP2C19KCNH2 | |
| SCHEMBL14620911 | 0.87 | CCR1 (0.72) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1638587 | 0.87 | CCR1 (0.72) | CCR1CYP2C19KCNH2 | |
| SCHEMBL10063618 | 0.87 | CCR1 (0.54) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| EP-2155712-B1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8481545-B2 | 3-(imidazolyl)-pyrazolo[3,4-b] pyridines | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7960388-B2 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | CHEMOCENTRYX, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960388-B2 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | CHEMOCENTRYX, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | CHEMOCENTRYX, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | CHEMOCENTRYX, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7629344-B2 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | CHEMOCENTRYX, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629344-B2 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | CHEMOCENTRYX, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2008147815-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008147822-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 3044/4885KCNH2 4405/4885 |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 2476/4885KCNH2 4629/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 2476/4885KCNH2 4629/4885 |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 3044/4885KCNH2 4405/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 2476/4885KCNH2 4629/4885 |
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | SOST, VDR, PTH1R | CCR1 1499/4885CYP2C19 2515/4885KCNH2 2862/4885 |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 3044/4885KCNH2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.